Cleared Traditional

K944375 - N/T RHEUMATOLOGY CONTROL SL/1, SL/2

K944375 is an FDA 510(k) clearance for N/T RHEUMATOLOGY CONTROL SL/1, manufactured by Behring Diagnostics, Inc.. The device is a Class 2 Immunology device with product code DCK cleared through the Traditional 510(k) pathway after a 26-day FDA review.

K944375 · Behring Diagnostics, Inc. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Oct 1994
Decision
26d
Days
Class 2
Risk

K944375 is an FDA 510(k) clearance for the N/T RHEUMATOLOGY CONTROL SL/1, SL/2. Classified as C-reactive Protein, Antigen, Antiserum, And Control (product code DCK), Class II - Special Controls.

Submitted by Behring Diagnostics, Inc. (Westwood, US). The FDA issued a Cleared decision on October 3, 1994 after a review of 26 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5270 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Behring Diagnostics, Inc. devices

FDA 510(k) Submission Details - K944375

510(k) Number K944375 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 07, 1994
Decision Date October 03, 1994
Days to Decision 26 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Statement
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
79d faster than avg
Panel avg: 105d · This submission: 26d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

DCK Device Classification - Class 2, Special Controls

Product Code DCK C-reactive Protein, Antigen, Antiserum, And Control
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5270
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - DCK C-reactive Protein, Antigen, Antiserum, And Control

All 105
Devices cleared under the same product code (DCK) and FDA review panel - the closest regulatory comparables to K944375.
DUPONT DIMENSION C-REACTIVE PROTEIN METHOD
K945280 · Dupont Medical Products · Mar 1995
LIQUISPEX(TM) LIQUID CRP CONTROL LEVEL 1 AND 2
K946050 · Clinical Controls, Inc. · Feb 1995
HEMAGEN C-REACTIVE PROTEIN KIT (EIA METHOD)
K944288 · Hemagen Diagnostics, Inc. · Oct 1994
TINA-QUANT CRP
K930621 · Boehringer Mannheim Corp. · Mar 1993
VIGIL II
K920845 · Beckman Instruments, Inc. · Dec 1992
ACCUTEX CRP LATEX TEST
K924332 · J.S. Medical Assoc. · Dec 1992